You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Proteasome inhibitor re-sensitizing molecules for treatment of refractory multiple myeloma

    SBC: Leukogene Therapeutics Inc.            Topic: 102

    Project Summary Abstract Multiple MyelomaMMis the second most common form of blood cancer and remains an incurable and deadly diseaseProteasome inhibitorPItherapy is a cornerstone in the treatment of MMbut resistance to this class of agent is an emerging challenge in the clinicNew therapeutic approaches that specifically target resistance are needed to maximize responses and ultimately produce cur ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  2. Testing and Commercialization of a Superior Device to Maintain Perioperative Normothermia In Anesthetized Patients

    SBC: Mercury Biomed LLC            Topic: 300

    Project SummaryAbstractThis proposal presents Phase II of Mercury Biomedandapos s plan for commercializing the new and innovative WarmSmart technology to more effectively keep surgical patients normothermicWarmSmart embodies several breakthrough concepts in bioheat transfer to manage core temperatureWe are building a costcompetitive patient warming technology that will be superior to existing tech ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  3. Making Standing Balance The Fifth Vital Sign in Clinical Settings

    SBC: Bertec Corporation            Topic: NIA

    Falls are a significant source of early morbidity and mortality in the aging population, yet the neurological,sensory, and motor changes that lead to increased fall risk often escape early identification and intervention. Vital signs are commonly used in clinical settings to assess the cardiovascular system (blood pressure, heart rate), immune system (body temperature), and the respiratory system ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  4. Compatibility between Brain-Computer Interface and High-Efficiency Augmentative and Alternative Communication Systems

    SBC: Prentke Romich Company            Topic: NIDCD

    Compatibility Between Brain-Computer Interface and High Efficiency Augmentative and Alternative Communication Systems: Phase II ABSTRACTBrain-computer interfaces (BCI) enable text production for people who cannot move, but have only simple communication interfaces and are not widely used. Augmentative and alternative communication (AAC) systems are widely used and give efficient and precise commun ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  5. Evolution of an Adaptable Prosthetic Foot Design for Normalization of Biomechanics During Community Participation

    SBC: OHIO WILLOW WOOD COMPANY, THE            Topic: NICHD

    Evolution of an Adaptable Prosthetic Foot Design for Normalization ofBiomechanics During Community Participation Summary/AbstractThe vision of this project is to improve the functional physical mobility of people with lower extremity amputations especially on uneven ground, side-slopes or when foot placement varies from side-to-side. People with amputations will be enabled to confidently participa ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  6. Development of an Autism Spectrum Disorder Screening Test based upon Metabolic Profiling of Fresh Blood Samples

    SBC: CIRCA BIOSCIENCE, LLC            Topic: 102

    Autism spectrum disorderASDis a neurodevelopmental disorder characterized by significant deficits in reciprocal social interactionsimpaired communication and restrictedrepetitive behaviorswith a prevalence ofinchildren in the USEarly intervention programs have been shown to be effective for improving IQlanguageand social skills for toddlers as young asmonths of ageDiagnosis of ASD is currently bas ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  7. Extending WAAVES+: An animal and environment-agnostic, automated USV scoring platform for high-throughput social, behavioral, and neuropharmacological studies

    SBC: Cornerstone Research Group, Incorporated            Topic: 101

    Project SummaryUltrasonic vocalizations (USVs) are known to reflect emotional processing, brain neurochemistry and brain function - key observations in animal model studies. Collecting and processing USV data is time-intensive, manual, and costly. Most importantly, it limits researchers’ ability to employ fully effective, and nuanced experimental designs, and is a barrier to entry for other rese ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  8. Aminoglycosides with reduced ototoxicity via miRNA targeting

    SBC: NUBAD, LLC            Topic: NIAID

    PROJECT SUMMARYAminoglycosides are one of the cheapest and well-known antibiotics in clinical use for over 70 years, but one of the major limitations in their use is their ototoxicity. We are developing fast and low cost methods to develop aminoglycosides with anti- ribosomal activities and reduced toxicity. In this project, we will identify novel aminoglycoside antibacterials, that show reduced o ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  9. Nucleobase aminosugars with reduced ototoxicity

    SBC: NUBAD, LLC            Topic: Y

    PROJECT SUMMARYAminoglycosides are one of the cheapest and well known antibiotics in clinical use for overyearsbut one of the major limitations in their use is their ototoxicityWe are developing fast and low cost methods to develop aminoglycosides with antiribosomal activities and reduced toxicityIn this projectwe will identify novel aminoglycoside antibacterialsthat show reduced ototoxicityComple ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  10. Evaluation of therapeutic efficacy and safety of novel small RNA target delivery platform in vivo.

    SBC: Oncoimmune Inc            Topic: 100

    Project Summary AbstractThe recent rapid expansion of genomic data greatly contributes to the understanding of disease development and progressionTo translate these genetic discoveries into clinical applicationswe need to develop therapeutic platforms that can specifically modulate the expression of disease related genes in vivoSmall RNAssuch as microRNAs and siRNAs function in messenger RNA silen ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government